Pharmaceutical care to pregnant women carrying human immunodeficiency virus by Romeu, Geysa Aguiar et al.
*Correspondence: G. A. Romeu. Centro de Ciências da Saúde, Universidade 
de Fortaleza, Av. Washington Soares, 1321 – Bloco C - Edson Queiroz, 60811-
905 - Fortaleza - CE, Brazil. E-mail: geysa@unifor.br
A
rt
ic
leBrazilian Journal of 
Pharmaceutical Sciences
vol. 45, n. 3, jul./sep., 2009
Pharmaceutical care to pregnant women carrying human 
immunodeficiency virus
Geysa Aguiar Romeu1,2*, Larissa Varela de Paiva1, Mariana Mota Moura Fé2
1Course of Pharmacy, Health Sciences Center, University of Fortaleza (UNIFOR),
2District Hospital Gonzaga Mota Messejana (DHGMM)
The purpose of this present study was to know the pharmacoepidemiological profile of pregnant women 
carrying HIV, the prevention actions against vertical transmission, and evaluate the service respecting the 
patients’ level of satisfaction. It was developed a quali-quantitative longitudinal study, with the sample 
being composed by pregnant women carrying HIV attended at the Pharmaceutical Care Service of a 
public hospital of Fortaleza – state of Ceará, during the period between January and September, 2007. 
The data were collected by means of follow-up cards, patients’ medical history and, finally, interviews 
to verify the users’ level of satisfaction related to the service. Twenty seven pregnant and parturient 
women have participated in the study. The mean profile found was of a single woman, aged in the range 
between 18 and 28 years, of Caucasian race or dark colored, with familial revenue below the minimum 
wage, having elementary or high school, and being unemployed. It was observed that 77.8% (n=21) of 
patients followed all prevention strategies against maternal-infant transmission. Twenty nine drug related 
problems have been detected, out of which 51.7% (n=15) were resolved. The general level of satisfaction 
respecting the Pharmaceutical Care Service was quite satisfactory. By means of the Pharmaceutical Care 
Service, the pharmacist professional effectively collaborates for the correct utilization of medications, 
and this action results directly in a decrease of HIV vertical transmission.
Uniterms: Pharmacoepidemiology. Pharmaceutical Care. HIV. Pregnant women/pharmacoepidemiological 
profile.
Objetivou-se com o presente estudo conhecer o perfil farmacoepidemiológico das gestantes portadoras do 
vírus HIV, as ações de prevenção da transmissão vertical e avaliar o serviço quanto ao nível de satisfação 
das pacientes. Realizou-se estudo quali-quantitativo, longitudinal, sendo a amostra composta pelas 
gestantes portadoras do vírus HIV atendidas no Serviço de Atenção Farmacêutica de um hospital público 
de Fortaleza-CE, no período de janeiro a setembro de 2007. Coletaram-se os dados por meio de fichas de 
seguimento, prontuários das pacientes e, finalmente, entrevistas para verificar o nível de satisfação das 
usuárias em relação ao serviço. Participaram do estudo 27 gestantes e parturientes infectadas pelo HIV. 
O perfil encontrado foi de mulheres solteiras, na faixa etária de 18 a 28 anos, de cor branca ou parda, 
com renda familiar inferior a um salário mínimo, com ensino fundamental ou médio e desempregadas. 
Observou-se que 77,8% (n=21) pacientes seguiram todas as estratégias de prevenção da transmissão 
materno-infantil. Detectaram-se 29 problemas relacionados ao uso de medicamentos, dos quais 51,7% 
(n=15) foram resolvidos. O nível de satisfação geral em relação ao serviço de atenção farmacêutica foi 
bastante satisfatório. Por meio do serviço de atenção farmacêutica, o profissional farmacêutico colabora 
com a utilização correta dos medicamentos, podendo repercutir diretamente na redução da transmissão 
vertical do HIV.
Unitermos: Farmacoepidemiologia. Atenção Farmacêutica. HIV. Gestante/perfil farmacoepidemiológico.
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INTRODUCTION
It is called vertical transmission (VT) of the human 
immunodeficiency virus (HIV) the phenomenon of infant 
infection occurring during pregnancy, and at parturition 
or puerperium by means of breast-feeding. However, the 
newborn from a mother carrying HIV has the opportu-
nity to do not self-infect. Currently, there are effective 
measures to avoid the risk of transmission, such as: the 
early diagnosis of infected pregnant women, the use of 
antiretroviral drugs (ARV), the programmed cesarean 
section, and the suspension of breast-feeding. During the 
prenatal phase, all pregnant women have the right and 
should consummate the test for HIV detection. As early is 
done the diagnosis, as better are the chances to avoid the 
transmission to the newborn (Brazil, 2006).
It is estimated that in Brazil, more than 17 thousand 
pregnant women infected by HIV give birth every year, 
however, only about seven thousand women receive pro-
phylaxis with ARV at the moment of delivery (Falci, Bay, 
2006). The maternal-infant transmission of HIV continues 
to be the main path of newborn infection, a fact that is res-
ponsible for more than 90% of reported cases of acquired 
immunodeficiency syndrome (AIDS) in this population 
(Castro et al., 2001; Falci, Bay, 2006; Sbalqueiro et al., 
2004; Yoshimoto, Diniz, Vaz, 2005). Up to 2005 June, 
370,499 cases of HIV infection/AIDS had been reported 
in Brazil, being 118,520 in women (31.9%) (Romanelli et 
al., 2006). Due to this progressive growth in the number 
of AIDS cases between women, mainly in women at re-
productive age, the VT is assuming great epidemiologic 
importance (Brito et al., 2006; Cavalcante et al., 2004; 
Lemos, Gurgel, Fabbro, 2005; Romanelli et al., 2006).
The evaluation of pregnant women respecting to 
immunosuppression and risk of vertical transmission is 
done through the determination of T-CD4 lymphocytes 
and viral load, with samples collected ideally before to 
start the use of ARV. This intervention is done during the 
pregnant women follow-up and after the stage of counse-
ling. The gravid women should have available the deve-
lopment of these examinations, so that they could start as 
early as possible the prophylaxis with ARV. The treatment 
of pregnant women should be individualized, taking into 
account their examinations and their medicative past; it 
should be clarified to every patient if the strategy aims 
only the transmission prevention, or, otherwise, there are 
ARV criteria for treatment, requiring so its maintenance 
after delivery (Falci, Bay, 2006).
The main purpose of ARV therapy is to delay the im-
munodeficiency progression and/or restore the immunity 
as much as possible, increasing so the time and quality of 
life of infected person. However, the natural evolution of 
HIV infection is characterized by intense and continuous 
viral replication occurring within many cellular and ana-
tomic compartments, which results, mainly, in the des-
truction and dysfunction of T-lymphocytes expressing the 
membrane antigen CD4 (T-CD4 lymphocytes) and other 
cells of the immune system. The progressive depletion 
of T-CD4 lymphocytes, together with other quantitative 
and qualitative alterations of the immune system, leads to 
immunodeficiency, which, in its more severe form, mani-
fests itself by the appearance of opportunistic infections 
and neoplasias, which are AIDS characteristics. Therefore, 
the maximal suppression of viral replication is desirable, 
in order to decrease or reverse the immunologic damage 
(Brazil, 2006). 
A great barrier for the implementation of ARV use 
in HIV infected pregnant women is the lack of a prenatal 
assistance. The moment of virus transmission from the 
mother to her fetus is crucial and it is necessary to inter-
vene with ARV drugs during the prenatal assistance, at 
labor, as well as administering these drugs to the newborn. 
In Brazil, although ARV medications are available for all 
pregnant women population infected by HIV and their 
respective infants, the difficulties of public health network 
to provide laboratory diagnosis for this infection, and the 
insufficient coverage respecting the women tested during 
the prenatal phase, result in the administration of injecta-
ble zidovudine (AZT) in less than 50% of the deliveries 
of pregnant women who are, probably, infected by HIV 
(Brazil, 2006).
In a research developed in 1994, it was evidenced 
a significant decrease in the rate of VT, from 25.5% to 
8.3%, with the use of AZT in pregnant women and their 
newborn (Connor et al., 1994). Therefore, it is possible 
to assert that the correct use of ARV is of fundamental 
importance to decrease the rates of VT. In this setting, the 
Pharmaceutical Care (PC) appears as a practice focused on 
the patient, where the pharmacist is the professional that 
could effectively contribute for the adequate use of ARV, 
adopting for that, therapeutic strategies of easy unders-
tanding as well as establishing a friendly and confidential 
relationship with patients, in order to clarify all doubts that 
could occur respecting the use of medication (Lyra Júnior 
et al., 2004; Storpirtis, Ribeiro, Marcolongo, 2000). 
Due to infection severity and taking into account 
the possibility of a VT decrease, it becomes important the 
access of pregnant women to a Service of Pharmaceutical 
Care, during the use of ARV in the prenatal phase (Sbal-
queiro et al., 2004). In this type of specialized service, 
the pharmacist passes to follow-up better the patient, 
knowing not only the used medication, but also the way 
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the patient uses it, beyond to obtain information about the 
patient’s personal feelings respecting the treatment and 
respective health problem. In the practice, the pharmacist, 
in an organized way, collects and evaluates information 
respecting the patient, including the identification of pos-
sible problems related to the use of medicines, which are 
known as Drug Related Problems (DRP). Once identified 
a problem, the pharmacist looks for a solution, formulates 
and puts into practice a therapeutic plan to correct it. The 
Pharmaceutical Care is much diffused nowadays and re-
presents a desired activity for many pharmacists (Cebrim/
CFF, 2006).
However, the orientation provided by the pharmacist 
aims not only at the prevention, detection of DRP, and 
resolution of negative results related to medicines (Me-
dication Negative Results - MNR), but also the patients 
education respecting the use of medicines, the interaction 
between the pharmacist and other healthcare professionals, 
a pathologic follow-up of the patient in order to optimize 
the pharmacotherapy, and the effective participation of 
the professional in the community (Cebrim/CFF, 2006).
The inadequate AIDS pharmacotherapy, besides to 
constitute an important public health problem all over the 
world, with great social and economical consequences, 
brings the risk of transmission to the infant, in case of 
HIV infected pregnant women. The sensitization of these 
patients, respecting the importance of treatment adherence 
and adequate use of medicines, provides higher effective-
ness and safety for their pharmacologic treatment.
The Pharmaceutical Care Service for pregnant pa-
tients carrying HIV was implanted in the District Hospital 
Gonzaga Mota Messejana (DHGMM), in 2007 January, 
having as a purpose to contribute to decrease the VT. The 
intention in this work, therefore, is to know the profile of 
patients attended in this service, their access to actions 
for VT prevention and control, as well as to evaluate the 
service by means of the satisfaction level of patients, in 
order to establish proposals for its improvement. 
MATERIAL AND METHODS
This is a quali-quantitative longitudinal study de-
veloped in the period between January and September, 
2007, in the District Hospital Gonzaga Mota Messejana 
(DHGMM), a secondary hospital localized in Fortaleza-
Ceará-Brazil, attending mainly women looking for ser-
vices of gynecology and obstetrics, and having 84 beds. 
As an average, about six thousand women are attended 
monthly over there.
The Service of Specialized Attendance in Mater-
nal-infant HIV/AIDS at DHGMM was started in 2005, 
endowed of infectology clinics for the pregnant women 
carrying HIV, and pediatric infectology service, besides 
prenatal follow-up, parturition and post-parturition 
attendance, psychosocial and nutritional assistance 
for the serum-positive pregnant women as well as for 
children in this same situation, which is extended up to 
their seroconversion or positive serology confirmation 
for HIV. It was the first clinical service in HIV offered 
by the city of Fortaleza, with the merit to be the se-
cond in the state of Ceará to attend children. It offers 
also the Pharmaceutical Care Service where the ARV 
medications are dispensed with the due orientations, 
assuring so the access of users to these drugs, which 
are regularly made available by the Ministry of Health. 
It is developed even the laboratory follow-up with the 
execution of CD4 and Viral Load examinations, which 
is occurring since the service registration as a requester 
unit, close to the Ministry of Health/National Program 
of STD/AIDS/Laboratory Unit (Secretaria Municipal 
de Fortaleza, 2007).
During the study period, 38 pregnant or parturient 
women carrying HIV have been registered in the Counse-
ling Program of STD/AIDS. Those who participated in the 
Pharmaceutical Care Service have been included, being 
excluded those who had less than three pharmaceutical 
consultations, and those who did not agree in participate 
of this research.
The study was divided into two steps. In the first one, 
pharmacoepidemiological data were collected by means 
of pharmacotherapeutic follow-up cards and patients’ 
medical history, being observed the following variables: 
personal information, obstetrical history, contamination 
path, moment of serology identification, execution of 
prenatal evaluation and number of consultations, access 
to prophylactic measures against vertical transmission, 
data respecting the pharmacotherapy, and description and 
classification of problems related to use of medications, 
or Drug Related Problems (DRP). It was adopted the 
DRP classification according to the Second Consensus of 
Granada (Comité de Consenso, 2002): 
Necessity:
DRP 1 – the patient presents a health problem due to non-
utilization of a necessary medication;
DRP 2 – the patient presents a health problem due to uti-
lization of an unnecessary medication;
Effectiveness:
DRP 3 – the patient suffers a health problem as a conse-
quence of a non-quantitative ineffectiveness of 
medication;
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DRP 4 - the patient suffers a health problem as a con-
sequence of a quantitative ineffectiveness of 
medication;
Safety:
DRP 5 - the patient suffers a health problem as a conse-
quence of a non-quantitative unsafety of medi-
cation;
DRP 6 - the patient suffers a health problem as a conse-
quence of a quantitative unsafety of medication.
The second step was composed by an interview 
to verify the grade of comprehension of the orientations 
about the use of ARV, and the satisfaction level of users 
respecting the Pharmaceutical Care Service. It was utilized 
a questionnaire pre-validated by Lyra Júnior et al. (2004), 
composed by four dimensions: quality of orientation; 
pharmacist consideration respecting to patients; profes-
sional competence, and pharmacotherapy management. 
The questionnaire is formed by 14 questions, every one 
with a scale composed by five alternatives (always, almost 
always, sometimes, almost never, never). The application 
of this instrument was developed individually, in a privati-
ve place, only with patients who authorized the interview, 
after signing an informed consent form.
The data were analyzed using the software Epi-Info 
version 3.4.1 and the results were organized in the form 
of tables. The study has followed the ethical precepts for 
research involving human beings, according to Resolution 
# 196/96 of National Health Council, being approved by 
the Institutional Review Board/Independent Ethics Com-
mittee of the University of Fortaleza.
RESULTS
From January to September, 2007, 38 patients were 
registered in the program STD/AIDS of DHGMM, out of 
which 71.0% (n=27) were attended at the Pharmaceutical 
Care Service, and all of them were included in the 1st 
phase of the research. Out of these patients, 55.5% (n=15) 
answered the service questionnaire of evaluation (2nd pha-
se). Table I describes their demographic characteristics. 
The mean profile of patients carrying HIV attended at 
DHGMM is of a single woman, aged in the range between 
18 and 28 years, of Caucasian race or dark colored, with 
familial revenue below the minimum wage, having ele-
mentary or high school, and being unemployed.
Respecting to habits, it was verified that 81.5% 
(n=22) of the interviewed women did not smoke and 
88.9% (n=24) did not consume teas frequently. No one had 
the habit of drink coffee and practice physical exercises, 
only 3.7% used to ingest alcoholic beverages, while the 
remaining ones did not present this habit.
When started the pharmacotherapeutic follow-up, 
85.2% (n=23) of patients were pregnant and 14.8% (n=4) 
parturient, being that 37.0% (n=10) reported that their 
pregnancy was not planned, nevertheless they accepted 
to be submitted to prenatal evaluation, and utilized the 
ARV drugs with prophylactic purpose. Out of the patients 
knowing their seropositivity before the pregnancy (37.0%; 
n=10), three stated that the pregnancy was planned. The 
remaining ones (63.0%; n=17) discovered to be seropo-
sitive on occasion of the anti-HIV test, done at prenatal 
evaluation. The majority of patients (63.0%) started the 
prophylaxis with ARV at the third quarter of pregnancy. 
Respecting to contamination path, the information was 
available for 59.2% (n=16) of cases and, out of these 
patients, 87.5% (n=14) were infected by means of sexual 
contact with the respective mate (51.9% of total) (Table II).
Satisfactory results were obtained respecting to 
prevention strategies against vertical transmission, being 
observed that 92.6% (n=25) patients have done the anti-
HIV test in the prenatal evaluation and 88.9% (n=24) 
utilized ARV during the prenatal phase. Injectable AZT 
was administered during the cesarean operation of 85.2% 
(n=23) pregnant women, and all of them have suspended 
the breast-feeding. Respecting to use of oral AZT by the 
newborn, only one has taken it in the first 24 hours, and 
all of them utilized the medication during their first six 
weeks of life. All the prevention strategies were followed 
by 77.8% (n=21) of patients (Table III).
Table IV demonstrates that, out of the patients that 
used ARV in the prenatal phase (88.9%; n=24), 87.5% 
(n=21) received a first-choice therapy, according to recom-
mendations from the Ministry of Health (Brazil, 2006). 
A proportion of 95.8% presented high level of treatment 
adherence. Respecting to duration time of prophylaxis, the 
majority utilized ARV during 1 to 3 months, confirming the 
treatment beginning from the third quarter of pregnancy.
Twenty nine problems related to use of medications, 
or Drug Related Problems (DRP), were detected, resul-
ting in an average of 1.1 DRP per patient, with variation 
of 0 to 8. The categories of necessity, effectiveness, and 
safety have presented, respectively, in 14, 4 and 11 cases, 
being detected the DRPs 1, 4 and 5 as the more preva-
lent ones (Table V). The main adverse reactions related 
DRPs (DRP 5) were nauseas and vomits (7.4%), anemia 
(7.4%), diarrhea (11.1%), cutaneous rash, dizziness, 
headache and cloudy vision (3.7% each). Respecting to 
accomplishment of pharmacological treatment, cases 
of forgetfulness (7.4%), utilization of wrong quantity 
of medication (14.8%), treatment suspension for one’s 
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own hand (3.7%) due to occurrence of adverse reaction, 
and treatment desertion (3.7%) due to non-acceptance of 
seropositive condition were verified. Nineteen pharma-
ceutical intervention were developed and 51.7% (n=15) 
of problems were resolved. 
The questionnaire utilized in the present study 
has evaluated the quality of orientations, the pharmacist 
consideration respecting to patients, the professional com-
petence, and the pharmacotherapy management, as well 
as the patients’ general satisfaction with the service. The 
satisfaction with both, the pharmacist and the program, 
has presented very adequate results, as demonstrated at 
Table VI. All interviewed women have considered that the 
pharmacist had always oriented respecting the adequate 
use of medications (questions 3, 4, and 6). The doubts 
were always clarified, and the pharmacist had been always 
available for the necessary orientations (questions 7, 8, 
and 12). No patient has felt difficulty to understand the 
pharmacist (question 11). Respecting to the time availa-
ble for PC sessions, the sessions lasted an average of 30 
minutes, and it was enough to receive the adequate infor-
mation (questions 1 and 7). Respecting the professional 
competence and pharmacotherapy management, it was 
TABLE I - Distribution of patients carrying human immuno-
deficiency virus (HIV), according to age range, civil status, 
race, familial revenue, scholarship, and profession (n=27) 
(DH)
Variables N %
Age range
18 to 28 15 55.6
29 to 39 12 44.4
Civil status
Single 10 37.1
Married 5 18.5
Separate 5 18.5
Stable union 5 18.5
Not informed 2 7.4
Race
Caucasian 9 33.3
Dark 9 33.3
Black 5 18.5
Not informed 4 14.8
Familial revenue
< 1 minimum wage 9 33.3
1-2 minimum wages 6 22.2
2-3 minimum wages 1 3.7
Not informed 11 40.7
Scholarship
Illiterate 4 14.8
Elementary school 11 40.7
High school 11 40.7
Not informed 1 3.7
Profession
Housewife 10 37.1
Seamstress 2 7.4
Charwoman 2 7.4
Other 4 14.8
Not informed 9 33.3
TABLE II - Distribution of patients carrying human immuno-
deficiency virus (HIV) according to obstetric history, 
contamination path, serology identification, prenatal evaluation 
execution, and the number of prenatal consultations (n=27) 
(DHGMM, 2007)
Variables nº %
Obstetric situation
Pregnant woman 23 85.2
Parturient 4 14.8
Planned pregnancy
Yes 6 22.2
No 10 37.0
Not informed 11 41.0
Gestational age 
2nd quarter 4 14.8
3rd quarter 17 63.0
Not informed 6 22.2
Contamination path
Sexual (mate) 14 51.9
Sexual violence 2 7.4
Not informed 11 40.7
Serology identification
Prenatal 17 63.0
Before pregnancy 10 37.0
Prenatal evaluation
Yes 25 92.6
No 2 7.4
Number of prenatal consultations
1 to 4 10 37.0
5 to 8 15 55.6
Not informed 2 7.4
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observed that 93.3% of patients affirmed that the pharma-
cist explained about the possible side effects caused by the 
new medication (question 2), and no patient reported that 
the pharmacist’s explanations were not as detailed as they 
should be (question 5). The presence of dispersing factors 
in the PC room was mentioned by 14.3% of interviewed 
women (question 13). All of the attended women were 
satisfied with the service attendance (question 14).
DISCUSSION
The HIV epidemic is progressively advancing over 
the female population as a result of the increased heterosex-
ual transmission, bringing negative effects for this popula-
tion, as well as the possibility of HIV vertical transmission, 
a twofold malefic event (Lemos, Gurgel, Fabbro, 2005). 
Epidemiologic data have shown that, in Brazil, the major-
ity of AIDS cases in women occur in the lower scholarship 
stratum and between those with less qualified occupation. 
Correspondingly to this situation, a growing impoverish-
ment of the population assaulted by HIV occurs as well 
(Moura, Praça, 2006). The studied sample has provided 
results that are similar to those of the literature (Castro et 
al., 2001; Sbalqueiro et al, 2004), where the mothers are 
young, in the reproductive phase, possess lower scholarship 
and familial revenue, with the majority being housewives 
and do not living a stable union. These findings correspond 
also to country official data respecting the involvement of 
women with lower scholarship and revenue in the AIDS 
epidemic (Moura, Praça, 2006).
During pregnancy, HIV infection brings many con-
sequences, of physical and emotional nature, for both, the 
pregnant woman and respective conception. For many 
times, the diagnosis is done during the prenatal phase, and 
could result in non-acceptance of serological findings by 
the patient, who could further deny to be submitted to any 
treatment or follow-up by healthcare professionals.
TABLE III - Distribution of patients carrying human immuno-
deficiency virus (HIV) according to access to prevention 
strategies against vertical transmission (n=27) (DHGMM, 2007)
Variables N %
Realization of anti-HIV test in the prenatal phase
Yes 25 92.6
No 2 7.4
Use of ARV in the prenatal phase
Yes 24 88.9
No 3 11.1
Use of Injectable AZT at delivery
Yes 23 85.2
No 4 14.8
Type of delivery
Cesarean 23 85.2
Vaginal 4 14.8
Use of oral AZT by the newborn 
First 24hours 26 96.3
During the first 6 weeks 27 100
Suspension of breast-feeding
Yes 27 100
Todas as etapas 21 77,8
ARV: Antiretroviral; AZT: Zidovudine.
TABLE IV - Distribution of patients carrying human immuno-
deficiency virus (HIV) according to use of first-choice anti-
retroviral (ARV) therapy, treatment adherence, and time of 
prophylaxis (n=24) (DHGMM, 2007)
Variables N %
First-choice ARV therapy
Yes 21 87.5
No 3 12.5
Treatment adherence
Yes 23 95.8
No 1 4.2
Time of prophylaxis (months)
< 1 2 8.3
1 to 3 18 75.0
> 4 4 16.7
TABLE V - Classification of problems related to use of 
medications, or Drug Related Problems (DRP), identified 
according to Second Consensus of Granada (n=29) (DHGMM, 
2007)
DRP category nº %
Necessity 14 48.3
DRP 1 13 92.8
DRP 2 1 7.1
Effectiveness 4 13.8
DRP 3 1 25.0
DRP 4 3 75.0
Safety 11 37.9
DRP 5 8 72.7
DRP 6 3 27.3
Total 29 100
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On the other hand, the opportunity for women to 
develop the HIV test in the prenatal phase assures their 
access to all steps of VT prevention. The great problem 
is the delay to obtain this examination result, which leads 
many of these women to start prophylaxis with ARV only 
at the third quarter of pregnancy. The work developed 
by Pluciennik (2003) has evidenced that the cost with 
serological tracking of pregnant women represents about 
80% of the total costs for prevention of maternal-infant 
transmission, and that an important part of these costs is 
due to losses and unnecessary repetitions of tests. The late 
starting of prenatal follow-up represents also a barrier for 
the prevention of vertical transmission. 
Castro et al. (2001) have described the study of 29 
cases of pregnancy between women infected by HIV-1 
virus. The main path of transmission was also sexual 
(41.4%) and the majority has obtained the infection diag-
nosis before the child birth (72.3%); however, the percent-
age of pregnant women that received prophylactic doses of 
ARV during pregnancy, in order to prevent VT, was lower 
(65.5%) than the one found in this present study (88.9%). 
Another worrying fact was that the majority of pa-
tients have started the prophylaxis only at third quarter of 
pregnancy, contradicting the professed by the Ministry of 
Health, that is, prophylaxis with ARV should be started from 
the 14th week of pregnancy forth. Nevertheless, the Ministry 
of Health itself affirms that “when the opportunity of ARV 
use at pregnancy beginning is lost, this therapy should be 
started at any gestational age, and the intravenous AZT 
should be settled at the moment of delivery”. One of the 
purposes of ARV prophylaxis is to enable pregnant woman 
to reach delivery moment with the lower viral load as pos-
sible, preferably undetectable or, at least, lower than 1,000 
viral copies per mL of serum (Brazil, 2006).
Out of the patients knowing their seropositivity 
before pregnancy, three stated that pregnancy was de-
sired, reporting that they wanted to generate a child and 
become mother, even being HIV bearer. The women that 
already knew their serologic status before pregnancy, 
had many more chances to receive all prevention phases, 
than those who knew their status only during pregnancy 
(Cavalcante et al, 2004); and considering that a planned 
pregnancy could decrease the risk for VT, in the extent 
that the levels of viral load and T-CD4 lymphocytes are 
effectively controlled, it is assumed that such situation 
is more favorable than a non-planned pregnancy (Silva, 
Alvarenga, Ayres, 2006).
On the other hand, it was evidenced the non-use at 
all, or the inadequate use of contraceptives and preserva-
tives, in the report of patients who knew their infected 
status and alleged undesired pregnancy. A study respecting 
the contraceptive behavior of 184 women bearing AIDS in 
Santo André – state of São Paulo has verified 51 (27.8%) 
undesired pregnancies, which were also related to mascu-
line preservative failures or non-use at all of contraceptive 
methods (Figueiredo, 2001)
A research mentioned by Castro et al. (2001) reveals 
that less than 50% of the patients who discover their HIV 
TABLE VI - Level of satisfaction of patients carrying human immunodeficiency virus (HIV) respecting the attendance provided by 
the pharmacist and respecting the Pharmaceutical Care program (n=15) (DHGMM, 2007)
Evaluated items %
1. Does the pharmacist spend with you as much time as necessary? 100
2. Does the pharmacist explain about the possible side effects caused by the new medication to you? 93.3
3. If you have some doubt respecting prescription, is there a pharmacist always available to give orientation to you? 100
4. Does the pharmacist give you explanations, in a way that you understand? 100
5. Are not the pharmacist explanations as detailed as they should be? 0
6. Does the pharmacist confirm if you have understood how to take the medications? 100
7. Does not the pharmacist, sometimes, spend enough time with you? 0
8. Is the pharmacist friendly with you? 100
9. Is the pharmacist a competent professional? 100
10. Do you need to wait for a long time before attendance by the pharmacist? 0
11. Have you some difficulty to understand the pharmacist? 0
12. Is the pharmacist sincerely interested in your personal case? 100
13. Are there (in the PC room) many dispersing factors harming your attention during the session? 14.3
14. Are you satisfied with the attendance received from the pharmacist? 100
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infection, effectively, decide to interrupt their pregnancy; 
and many of them become pregnant again. Another work, 
developed in Belo Horizonte – state of Minas Gerais, has 
shown that despite the majority of patients (67.6%) have 
presented only one pregnancy after knowing their infected 
status, patients with two to seven pregnancies after diag-
nosis have also been identified (Romanelli et al., 2006).
The two patients who were not submitted to prenatal 
examination received urgency care due to occurrence of 
home parturition. It is known that the majority of cases of 
VT of HIV occur during the labor and parturition (60% 
to 65%), and the remaining cases (35% to 40%) in the 
intrauterine period, mainly in the last weeks of pregnancy 
(Brazil, 2006). Therefore, the women who have their diag-
nosis at delivery moment or after it, loose all opportunities 
for development of prophylaxis (Cavalcante et al, 2004). 
The type of delivery has been largely discussed as a risk 
factor, being the elective cesarean operation associated to 
a lower risk for VT than the vaginal delivery (Brazil, 2006; 
Yoshimoto, Diniz, Vaz, 2005). 
Breast-feeding represents an additional risk for 
transmission of 7 to 22%. This risk increases, being of ap-
proximately 30%, when the mother infection occurs during 
the nursing period. Because of that, mothers are advised to 
suspend the breast-feeding (Brazil, 2006). However, Or-
tigão (1995) discusses that mother’s milk could be the single 
nutritional source for the nursling in low revenue families, 
making that the risk to take HIV becomes less relevant than 
the risk of death due to innutrition. This author quotes that 
the World Health Organization (WHO) recommends that in 
countries where infectious diseases and innutrition are the 
main causes for child mortality, the breast-feeding should 
be recommended for all mothers, including the ones with 
HIV infection. In Brazil, particular cases should be evalu-
ated for the adoption of conducts addressed to every region 
and social situation. Always as possible, the breast-feeding 
is counter-indicated and all efforts should be summed in 
order to provide adequate artificial feeding. All the patients 
attended at the service of Pharmaceutical Care develop this 
phase for prevention, passing the newborns to receive a 
lacteous formula offered by DHGMM.
Respecting the use of prophylactic antiretroviral 
(ARV), a study developed by Connor (1994) has dem-
onstrated a significant fall in the VT rate, from 25.5% to 
8.3%, with the use of AZT in the pregnant woman and the 
newborn. When all of the recommendations are followed, 
the VT rates achieve 1 to 2% (Brazil, 2006; Romanelli et 
al, 2006). This specific information is provided to patients 
during the exercise of Pharmaceutical Care, and increases, 
in such a way, the mother confidence and hope respecting 
the seronegativity of the newborn. The children of the 21 
patients who developed all the prevention phases, effec-
tively, have great chances to be free of virus contamina-
tion; however, the data referring to serological condition 
of these children are not available yet. Results obtained 
through the study of trend to VT after the settlement of 
ARV therapy in Brazil, beginning in 1996, have consis-
tently revealed the occurrence of a progressive decrease 
in the expected cases of AIDS due to VT, for children born 
from 1997 forth (Brito, et al., 2006).
When the intervention with zidovudine is developed 
belatedly in the pregnancy, and even only in the newborn, 
it is confirmed its efficacy in the decrease of VT (Brazil, 
2006). In this study, all the newborns utilized AZT syrup 
during the first six weeks of life, increasing the possibili-
ties for serological negativation.
During the Pharmaceutical Care, some problems 
related to use of medications, the so called Drug Related 
Problems (DRP), were detected; with the main ones being 
related to inadequate form of medication administration 
and appearance of adverse reactions, causing other health 
problems and, in some cases, harming the treatment ad-
herence. The data found were similar to those from other 
works (Lignani Júnior, Greco, Carneiro, 2001; Menezes de 
Pádua et al., 2006), in which adverse reactions appearance 
was detected, such as: nauseas, vomits, diarrhea, allergies, 
anemia, abdominal pains, fatigue, headache, insomnia, 
pruritus, exanthema, among others. 
The most frequently found DRP by Cerdá and Almi-
ñana (2004), in a program of Pharmaceutical Care for pa-
tients with HIV infection, are related to adherence (30%), 
adverse events (27%), overdose (13%), and sub-dose (9%). 
The proportions of adverse reactions and overdose of these 
authors research were similar to those found in this present 
study, but the level of adherence was lower and the occur-
rence of sub-dose was higher. The exercise of Pharmaceuti-
cal Care determines that, from the DRP identification forth, 
it is necessary to produce a specific procedure addressed to 
obtaining the better and more concrete results as possible, 
for the patient. It contemplates also the education and pre-
vention in the ambit of public health and, consequently, the 
information respecting recommendations addressed to help 
the rational use of medications.
The treatment adherence is referred to patient’s 
conduct to follow the medical prescription respecting to 
posology, quantity of drugs, time of treatment and special 
recommendations for given medications. The treatment ad-
herence is of fundamental importance in the case of acquired 
immunodeficiency syndrome, because incorrect drugs use 
is directly related to therapeutic failure and the appearance 
of HIV strains that are resistant to available medications 
(Lignani Júnior, Greco, Carneiro, 2001) 
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In studies mentioned by Lignani Júnior, Greco e 
Carneiro (2001) the rate of adherence to ARV varies be-
tween 40% and 80%. In another work developed in São 
Paulo and mentioned by the same authors, it was found an 
adherence rate of 73.8%. In this study, the adherence rate 
was of 95.8%, similar to that one found in the evaluation of 
a Pharmaceutical Care program addressed to improve the 
ARV treatment adherence in Spanish hospitals (94.8%). It 
is so suggested that the existence of a Pharmaceutical Care 
Service could improve the ARV treatment adherence, and 
it has been observed that patients maintaining an adher-
ence higher than 95% often present also a good virologic 
evolution (Jané et al., 2004). 
The pharmaceutical interventions were effective, 
favoring the decrease of symptoms caused by inadequate 
pharmacotherapy, and increasing the patients’ quality of 
life. The interventions consisted of orientation respecting 
the seropositive condition for HIV and the possibility of 
maternal-infant transmission, the importance of treatment 
adherence to avoid such transmission, the motivation to 
active participation in the proposed pharmacotherapy, the 
recognition of main adverse reactions, besides interven-
tions close to the responsible infectologist for pharmaco-
therapy alterations.
The satisfaction study has presented high scores for 
all approached domains, which has provided results that 
are similar to those found by Lyra Júnior et al. (2004), ex-
cept for the dispersing factors existing in the room utilized 
for the Pharmaceutical Care sessions. The non-existence 
of an appropriate consultation room for the practice of 
Pharmaceutical Care could embarrass the good progres-
sion of the proposed activities.
There is also the patients’ satisfaction respecting 
the service of Pharmaceutical Care as an important result 
reflecting the grade of involvement of the pharmacist, 
during the humanized clinical care, as well as the short-
ages and expectations from patients during the received 
attendances. The evaluation of patients’ satisfaction is an 
important measurement to assess the basic health atten-
dance and, more specifically in this work, it is recognized 
as a quality indicator of pharmaceutical services (Lyra 
Júnior et al 2004; Armando, Uema, Sola, 2005). 
It is considered that satisfied patients will continue to 
use the healthcare services, maintain specific links with the 
healthcare professionals, and accomplish the therapeutic 
regimens, obtaining so, the desired results of pharmacologic 
treatment (Armando, Uema, Sola, 2005). In this present 
study, it has been evidenced the high level of satisfaction 
from patients carrying HIV, justifying so the existence and 
continuity of Pharmaceutical Care Service at DHGMM.
CONCLUSION
Thanks to the detected number of Drug Related Pro-
blems, their respective resolution, and the great satisfaction 
of users respecting the service, it is possible to conclude that 
the pharmacist, when putting into practice the Pharmaceu-
tical Care, becomes a fundamental tool for the prevention 
and resolution of Drug Related Problems, which could 
result directly in a decrease of HIV vertical transmission. 
However, complementary studies including a control-
group, besides the children follow-up for definition of their 
serologic status are necessary for, definitely, determine the 
effective contribution of Pharmaceutical Care exercise for 
the decrease of HIV vertical transmission.
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